Efficacy of tislelizumab combined with gemcitabine and resulting changes in CT imaging for advanced non-small cell lung cancer

Background: The purposes of this study were to evaluated the efficacy and changes in computed tomography (CT) imaging associated with tislelizumab combined with gemcitabine for advanced non-small cell lung cancer (NSCLC). Material and Methods:This study examined 122 patients with advanced NSCLC who were treated at our hospital between January 2021 and October 2023.Subjects were categorized into the control group (gemcitabine monotherapy) and study group (tislelizumab + gemcitabine), with 61 patients in each group.Clinical efficacy, CT imaging changes (maximum lesion diameter, CT value, short diameter of metastatic lymph nodes), serum tumor markers (CA125, CEA, NSE), quality of life (FACT-L), drug safety, and survival outcomes were compared between groups.Results: The study group showed higher rates of objective remission (42.62%) and clinical control (86.89%) compared to the control group (18.03% and 62.30%, respectively, x 2 =8.728, 9.731, P